Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

BACKGROUND: Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhib...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Prostate Cancer Prostatic Dis
Main Authors: Ryan, Charles J, Dutta, Sandipan, Kelly, William K, Russell, Carly, Small, Eric J., Morris, Michael J., Taplin, Mary-Ellen, Halabi, Susan
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825875/
https://ncbi.nlm.nih.gov/pubmed/31053766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-019-0152-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker